Drug insight: the role of albumin in the management of chronic liver disease
- PMID: 17203088
- DOI: 10.1038/ncpgasthep0680
Drug insight: the role of albumin in the management of chronic liver disease
Abstract
Albumin is the most abundant protein in the circulation. Its main physiologic function is to maintain colloid osmotic pressure. Better understanding of albumin's other physiologic functions has expanded its application beyond maintenance of intravascular volume. In patients with cirrhosis, albumin has been used as an adjunct to diuretics to improve the diuretic response. It has also been used to prevent circulatory dysfunction developing after large-volume paracentesis. Newer indications in cirrhotic patients include preventing hepatorenal syndrome in those with spontaneous bacterial peritonitis, and treating established hepatorenal syndrome in conjunction with vasoconstrictor therapies. The use of albumin for many of these indications is controversial, mostly because of the paucity of well-designed, randomized, controlled trials. The cost of albumin infusions, lack of clear-cut benefits for survival, and fear of transmitting unknown viruses add to the controversy. The latest indication for albumin use in cirrhotic patients is extracorporeal albumin dialysis, which has shown promise for the treatment of hepatic encephalopathy; its role in hepatorenal syndrome or acute on chronic liver failure has not been established. Efforts should be made to define the indications for albumin use, dose of albumin required and predictors of response, so that patients gain the maximum benefit from its administration.
Similar articles
-
[The use of albumin infusion in decompensated liver cirrhosis].Ugeskr Laeger. 2002 Feb 25;164(9):1196-202. Ugeskr Laeger. 2002. PMID: 11899505 Review. Danish.
-
Albumin for end-stage liver disease.Korean J Intern Med. 2012 Mar;27(1):13-9. doi: 10.3904/kjim.2012.27.1.13. Epub 2012 Feb 28. Korean J Intern Med. 2012. PMID: 22403494 Free PMC article. Review.
-
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14. Gastroenterology. 2008. PMID: 18471512 Clinical Trial.
-
[Hepatorenal syndrome in patients with liver cirrhosis].Nephrol Ther. 2005 Jul;1(3):174-82. doi: 10.1016/j.nephro.2005.03.002. Epub 2005 May 31. Nephrol Ther. 2005. PMID: 16895684 Review. French.
-
Albumin infusion in liver cirrhotic patients.Acta Med Indones. 2010 Jul;42(3):162-8. Acta Med Indones. 2010. PMID: 20724771 Review.
Cited by
-
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5. Dig Dis Sci. 2016. PMID: 27048451
-
Aggregation-Induced Emission (AIE), Life and Health.ACS Nano. 2023 Aug 8;17(15):14347-14405. doi: 10.1021/acsnano.3c03925. Epub 2023 Jul 24. ACS Nano. 2023. PMID: 37486125 Free PMC article. Review.
-
Recent advances in our understanding of hepatorenal syndrome.Nat Rev Gastroenterol Hepatol. 2012 May 22;9(7):382-91. doi: 10.1038/nrgastro.2012.96. Nat Rev Gastroenterol Hepatol. 2012. PMID: 22614754 Review.
-
Spectrofluorimetric determination of human serum albumin using terbium-danofloxacin probe.ScientificWorldJournal. 2012;2012:940541. doi: 10.1100/2012/940541. Epub 2012 May 2. ScientificWorldJournal. 2012. PMID: 22645474 Free PMC article.
-
Critical evaluation of gamma-irradiated serum used as feeder in the culture and demonstration of putative nanobacteria and calcifying nanoparticles.PLoS One. 2010 Apr 26;5(4):e10343. doi: 10.1371/journal.pone.0010343. PLoS One. 2010. PMID: 20436679 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical